InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-18.0%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Smith Mark Alan, Directeur Médical. Insider active across 1 company, notably VistaGen Therapeutics, Inc.. Aggregated, 5 disclosures have been logged. Activity tracked since 30 June 2021. The latest transaction was disclosed on 30 June 2022 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations5 total
5,000 shares@ US$0.74819.0% of flowCommon StockSEC:0001415889-22-007687:0
2,655 shares@ US$1.657520.7% of flowCommon StockSEC:0001415889-22-000046
2,655 shares@ US$1.65750.016% mcap25.6% of flowCommon StockSEC:0001415889-22-000046:0
2,260 shares@ US$1.94650.015% mcap24.4% of flowCommon StockSEC:0001415889-21-003388:0
2,260 shares@ US$1.946519.8% of flowCommon StockSEC:0001415889-21-003388
5 of 5 declarations
About Smith Mark Alan
Smith Mark Alan serves as the Chief Medical Officer at VistaGen Therapeutics, Inc. He oversees the company's clinical and research initiatives, ensuring that drug development programs meet safety and efficacy standards. His role is crucial for innovation in the healthcare sector.
